Jim Cramer recently revealed which sector investors are 'complacently' positive about, and which one might be unfairly ...
With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
Eli Lilly and Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 512.66% and ...
The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist obesity medications.
Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...
Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 ...
According to the announcement, the share repurchase program allows for flexibility in purchasing methods, including open ...
Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) declared that its Board of Directors has approved a stock buyback program on Monday, December 9th, RTT News reports. The company plans to repurchase ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...